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Abstract
Central nervous system (CNS) diseases are difficult to treat because of the blood-brain barrier (BBB), which prevents most
drugs from entering into the brain. Intranasal (IN) administration is a promising approach for drug delivery to the brain,
bypassing the BBB; however, its application has been restricted to particularly potent substances and it does not offer
localized delivery to specific brain sites. Focused ultrasound (FUS) in combination with microbubbles can deliver drugs to
the brain at targeted locations. The present study proposed to combine these two different platform techniques (FUS+IN)
for enhancing the delivery efficiency of intranasally administered drugs at a targeted location. After IN administration of
40 kDa fluorescently-labeled dextran as the model drug, FUS targeted at one region within the caudate putamen of mouse
brains was applied in the presence of systemically administered microbubbles. To compare with the conventional FUS
technique, in which intravenous (IV) drug injection is employed, FUS was also applied after IV injection of the same amount
of dextran in another group of mice. Dextran delivery outcomes were evaluated using fluorescence imaging of brain slices.
The results showed that FUS+IN enhanced drug delivery within the targeted region compared with that achieved by IN
only. Despite the fact that the IN route has limited drug absorption across the nasal mucosa, the delivery efficiency of FUS+
IN was not significantly different from that of FUS+IV. As a new drug delivery platform, the FUS+IN technique is potentially
useful for treating CNS diseases.
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Introduction
Central nervous system (CNS) diseases are difficult to treat as
most systemically administered therapeutic agents cannot pene-
trate the blood-brain barrier (BBB). The BBB prevents the access
of ,100% of large-molecule drugs and ,98% of small-molecule
drugs (usually defined as smaller than around 500–600 Da in
molecular weight [1]) to the brain from the systemic circulation
[2]. Various strategies have been developed for circumventing the
BBB, such as invasive direct injection or infusion, modification of
therapeutic agents, and carrier-mediated transport [3]. Among
these strategies, intranasal (IN) delivery is a non-invasive approach
for direct drug delivery to the brain via the nose, bypassing the
BBB [4].
IN administration has emerged as a promising approach for
drug delivery to the brain. Traditionally, it has been successfully
used as a convenient method for drug delivery to the systemic
circulation, because IN administered drugs can be absorbed
through a rich vascular network in the nasal cavity into the
systemic circulation [5]. Although most drugs absorbed into the
blood circulation cannot enter the brain parenchyma because of
the BBB, it has been demonstrated feasible in animal and clinical
studies that drugs can be directly delivered from the nostrils to the
brain, bypassing the BBB. A wide-range of therapeutics, such as
peptides, proteins, gene vectors and stem cells, have been
successfully delivered through IN administration to small animal
brains and have shown efficacy in treating CNS diseases, such as
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease,
depression, anxiety, autism spectrum disorders, seizures, drug
addiction, eating disorders, and stroke [6–8]. Moreover, a number
of clinical trials have demonstrated CNS effects in humans
following IN delivery of biologics, among which IN administration
of insulin has been found to be a promising approach to slow down
the progression of Alzheimer’s disease [9].
Despite the fact that the mechanisms involved in IN drug
delivery to the brain are still being elucidated, some of the
pathways involved are known. The neural connections between
the nasal mucosa and the brain through the olfactory and
trigeminal nerves (involved in sensing odors and chemicals) have
been found to provide unique pathways for the noninvasive
delivery of therapeutic agents to the CNS [4,6]. IN administered
drugs are most likely transported extracellularly along the olfactory
and trigeminal nerves to the brain. The distribution of drugs from
these brain entry points to other distant CNS sites may be
envisioned to occur either by intracellular or extracelluar
transport. The extracellular transport can occur via convective
transport within the cerebral perivascular spaces, local diffusion at
the entry points, and local diffusion from perivascular spaces into
the parenchyma [4,6]. Although promising in brain drug delivery,
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the IN route has some disadvantages. One major drawback of this
route is that the fraction of drug reaching the CNS from the nasal
cavity is small, which has restricted its application to very potent
substances [6,10]. The other disadvantage is that drugs are
delivered to the whole brain through this route, while neurological
diseases do not generally affect the brain in a global manner.
Therefore, new strategies are needed for enhancing drug delivery
efficiency at the sites requiring treatment while minimizing the
exposure to other brain sites. Transcranial focused ultrasound
(FUS) in combination with microbubbles may offer such a
strategy.
FUS in combination with microbubbles can increase the BBB
permeability for targeted brain drug delivery with no or minimal
tissue damage [11,12]. The experimental design typically uses
intravenous (IV) injection of therapeutic agents with microbubbles,
and then applies FUS to induce BBB opening for drug delivery.
The FUS focuses externally generated ultrasound pulses through
the skull onto a small focal region (on the order of millimeters)
deep into the subcortical structures, which allows highly precise
and noninvasive targeting of brain regions where treatment is
desired. Microbubbles are micron-scale gas bubbles stabilized by a
lipid, protein, albumin or polymer shell. They have been used as
ultrasound imaging contrast agents in the clinic for more than two
decades and have shown great potential as drug delivery agents for
therapeutic applications. The FUS technique has been successfully
used in the delivery of various therapeutic agents, such as
chemotherapeutic drugs [13], neurotrophins [14], antibodies
[15], gene vectors [16], and cells [17]. Our group and others
have shown that the BBB opening induced by FUS is reversible,
and its closing time ranges from several hours to several days,
depending on the acoustic parameters [18]. The volume of BBB
opening can be controlled by adjusting the acoustic parameters or
microbubble sizes [19]. Previous short-term (up to 5-hr survival)
and long-term (up to 4-wk survival) safety assessment of the FUS
technique demonstrated that, when appropriate ultrasound
parameters are used, there is no or only minimal histological
damage [20,21]. Nevertheless, although IV injection of therapeu-
tic agents has high bioavailability, it is associated with systemic
exposure and thus not suitable for the delivery of drugs with short
half-lives in blood and/or high systemic side effects, such as
neurotrophic factors, neuropeptides, and hormones [8,22]. In
contrast, IN administration is a painless, simple, and noninvasive
approach that allows direct drug delivery to the brain, eliminating
the need for systemic delivery and thereby reducing associated side
effects [7,8].
The physical mechanisms for FUS-enhanced drug delivery have
been under extensive investigation [23,24]. Different from other
contrast agents used in medical imaging, microbubbles are
confined within the blood vessels after IV injection due to their
relatively large sizes. When microbubbles pass through the FUS
focal region, they cavitate, which is a broad term for ultrasound-
induced activities of bubbles, including their oscillation and
collapse. Cavitation is usually divided into two classes: stable
cavitation (bubbles stably oscillate) and inertial cavitation (bubbles
rapidly collapse). The cavitation emissions from microbubbles
during FUS sonication can be detected, allowing real-time
monitoring of the FUS treatment [25]. Microbubble cavitation
generates mechanical effects on the nearby blood vessels, such as
high shear stress, microstreaming, and microjetting, enabling
transvascular delivery of drugs in the blood circulation [26].
Meanwhile, the oscillating microbubbles can push and pull on the
blood vessels along with surrounding tissues, inducing expansion
and contraction of the perivascular spaces [27]. The displacements
of the perivascular spaces may induce convective bulk fluid flow,
leading to enhanced drug penetration. Moreover, the radiation
force generated by the FUS beam itself without microbubbles can
generate shear stress on the tissue and increase hydraulic
conductivity of the interstitial space, which can increase drug
diffusion [26]. The mechanical effects exerted by the FUS beam in
combination with microbubbles contribute to the enhanced brain
delivery of IV-injected therapeutic agents. These same mechanical
effects may also enhance the delivery of drugs administered
through the IN route.
Therefore, we hypothesized that FUS can enhance IN drug
delivery efficiency at the targeted brain sites. There were two
objectives of this study: (1) to explore the feasibility of this new
brain drug delivery strategy–FUS in combination with IN (FUS+
IN); (2) to compare the drug delivery outcomes of this new strategy
with the conventional approach–FUS coupled with IV injection
(FUS+IV). Wild-type mice were used as the animal model and a
40 kDa fluorescently-labeled dextran was used as the model drug
[28]. Dextrans are glucose polymers and the 40 kDa dextran was
selected as the model drug because its molecular weight is on the
same order of magnitude as many neurotrophic factors that have
considerable potential in the treatment of CNS diseases [22]. The
drug delivery outcomes using different strategies were evaluated
based on fluorescence images of brain slices.
Materials and Methods
Animal preparation
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Columbia University Institutional
Animal Care and Use Committee. All surgery was performed
under isoflurane anesthesia, and all efforts were made to minimize
animal suffering. The animal body temperature was maintained
using a heating pad.
A total of 26 male C57BL/6 mice (20–25 g in weight; Harlan
Laboratories, Indianapolis, IN) were used in this study. Among
these 26 mice, 20 were divided into the following four
experimental groups with n= 5 for each group. (1) Control group:
no dextran delivery and no FUS. (2) IN sham group: IN
administration of the dextran without FUS. (3) IN treatment
group: IN administration of the dextran with FUS applied on the
left side of the caudate putamen while the contralateral right side
was not sonicated. (4) IV treatment group: IV injection of the
dextran with FUS applied on the left side of the caudate putamen
while the contralateral right side was not sonicated. The remaining
6 mice were treated following the same protocol as groups 3 and 4
with n= 3 for each group for the purpose of assessing the safety of
the FUS treatment.
Microbubble generation
Microbubbles comprised of a 90 mol% 1,2-distearoyl-sn-
glycero-3- phosphocholine (DSPC) and 10 mol% 1,2-distearoyl-
sn-glycero-3- phosphoethanolamine-N-[methoxy(polyethylene gly-
col)2000] (DSPE-PEG2000) (Avanti Polar Lipids, Alabaster, AL,
USA) lipid-shell and a perfluorobutane (FluoroMed, Round Rock,
TX, USA) gas-core were manufactured in-house. Size-selected
microbubbles with a median diameter of 4–5 mm were isolated
from a poly-dispersed microbubble distribution using a differential
centrifugation method [29]. Their size distributions and concen-
trations were determined by a particle counter (Multisizer III,
Beckman Coulter Inc., Opa Locka, FL, USA). Before each
injection into the mouse, their concentrations were diluted using
Focused Ultrasound-Enhanced Intranasal Drug Delivery
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sterile saline to a final concentration of approximately 86108
number of microbubbles per mL.
Administration of the dextran
In the control group (group 1), no dextran was administered.
In the IN sham group (group 2) and IN treatment group (group
3), ,2 mg of 40 kDa Texas Red-labeled dextran (Life Technol-
ogies Inc, Grand Island, NY, USA) was administered intranasally
following procedures used before [4,30]. The dextran was
dissolved in saline at a concentration of 40 mg/mL. The
anaesthetized mice were placed supine with the head position
stabilized horizontally. A micropipette was used to intranasally
administer 3 mL drops of the dextran solution to alternating nostril
every 2 minutes. Drops were placed at the opening of the nostril,
allowing the animal to snort each drop into the nasal cavity. A
total of 51 mL dextran solution (,2 mg dextran) was delivered
over a course of 34 min.
For the IV treatment group (group 4), the same amount of
dextran (51 mL in volume, 40 mg/mL in concentration, and
,2 mg in dose) was administered by IV bolus injection through
the tail vein.
Focused ultrasound sonication
For the IN treatment group (group 3) and IV treatment group
(group 4), the mice were sonicated at a targeted brain location
using an experimental setup illustrated in Fig. 1(A) and following
an experimental timeline shown in Fig. 1(B).
A single-element FUS transducer (center frequency: 1.5 MHz,
focal depth: 60 mm, diameter: 60 mm; Imasonic, Besancon,
France) was driven by a function generator (33220A, Agilent,
Palo Alto, CA, USA) through a nominal 50 dB gain power
amplifier (325LA, E&I, Rochester, NY, USA). The lateral and
axial dimensions of the FUS focal region measured in water were
1.2 mm and 13.0 mm. A custom-built truncated cone was
attached to the transducer and filled with degassed water to
provide acoustic coupling. The cone was immersed in a degassed-
water container. The bottom of the water container had a window
sealed with an almost acoustically and optically transparent
membrane. The container was placed on the mouse head and
coupled with degassed ultrasound gel. Acoustic emissions arising
from microbubble cavitation were acquired by a pulse-echo
transducer (center frequency 10 MHz; focal length 60 mm;
Olympus NDT, Waltham, MA, USA). It was positioned through
a central hole of the FUS transducer and confocally aligned with
the FUS transducer. The signals received by the pulse-echo
transducer were amplified by 20 dB (Model 5800, Panametrics-
NDT, Waltham, MA, USA) and then digitized (Razor Express
CompuScope 1422, Gage Applied Technologies, Inc., Lachine,
QC, Canada) at a sampling frequency of 50 MHz.
Before FUS sonication, each mouse was positioned prone with
its head immobilized by a stereotaxic frame (David Kopf
Instruments, Tujunga, CA, USA). The fur on the mouse head
was removed with an electric clipper and a depilatory cream. A
modified 27G6K butterfly catheter (Terumo Medical, Somerset,
NJ, USA) was inserted into the tail vein for IV injection. The FUS
transducer was moved 2 mm lateral of the sagittal suture and
6 mm anterior of the lambdoid suture using a previously described
grid positioning method [31]. Freshly diluted microbubble
suspension (30 mL) was administered through a bolus injection
via the tail vein prior to each sonication. For the IV treatment
group (group 4), the microbubbles were co-injected with the
dextran (Fig. 1B). Immediately after injection (,5 s), pulsed FUS
(center frequency: 1.5 MHz; peak-negative pressure: 0.45 MPa;
pulse length: 6.7 ms; pulse repetition frequency: 5 Hz; duration:
1 min) was applied transcranially to the left caudate putamen. The
non-sonicated right caudate putamen served as control for IN
administration only (group 3) or IV injection only (group 4).
Additionally, prior to microbubble injection, a 30-s sonication
using the same acoustic parameters was applied in order to
measure the background cavitation signals, needed in the acoustic
emission analysis described later.
For all the mice used in the current study, a 1-h period was
allowed after finishing IN and IV dextran administration to enable
the dextran to diffuse into the brain parenchyma (Fig. 1B). At the
end of the allotted time, all mice were sacrificed by transcardial
perfusion. The mouse brains were processed and prepared for
either frozen (60 mm thick) or paraffin (6 mm thick) sections. The
frozen sections were imaged by a fluorescence microscope (BX61;
Olympus, Melville, NY, USA) and used later for quantifying
dextran delivery outcomes. The paraffin sections were used for
whole brain histological examinations by hematoxylin and eosin
(H&E) staining [21].
Acoustic emission analysis
The acoustic emission analysis method was the same as that
described previously [32–34]. To quantify the stable and inertial
Figure 1. Illustration of experimental (A) setup and (B) timeline. For IN administration, the dextran was administered 3 mL at a time,
alternating between the two nostrils, with a lapse of 2 min between each administration, over a total of 34 min.
doi:10.1371/journal.pone.0108880.g001
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cavitation behaviors of the microbubbles within the FUS targeted
region, the stable cavitation dose and inertial cavitation dose were
calculated, respectively.
For each ultrasound pulse, its frequency spectrum between 3
and 9 MHz was used for stable and inertial cavitation quantifi-
cation to eliminate any contributions from the FUS beam
(frequency = 1.5 MHz). The broadband emission from inertial
cavitation was obtained using a comb filter, which had a cut-off
band around each harmonic and ultraharmonic frequencies with
bandwidths of 350 kHz and 100 kHz, respectively. The root mean
square of the filtered spectra was calculated to represent the
inertial cavitation level for each pulse. The stable cavitation level
was obtained by first calculating the root mean square of the
amplitudes of all harmonics and then subtracting the correspond-
ing inertial cavitation level. The inertial cavitation activity was
thus not included in the stable cavitation quantification. The stable
and inertial cavitation doses were calculated by integrating the
stable and inertial cavitation levels over the total ultrasound
exposure time, respectively. The final doses were then calculated
by subtracting baseline doses obtained based on signals acquired
prior to microbubble injection.
Fluorescence analysis
The dextran delivery outcomes were determined by quantifying
the fluorescence intensities within the targeted caudate putamen.
Nine horizontal sections with four dorsal sections, four ventral
sections, and a reference midline section were selected from each
brain for the analysis. All the fluorescence images were first
normalized by their corresponding exposure time. Then, a circular
region-of-interest (ROI, diameter = 1.2 mm) was manually
aligned with the sonicated and control caudate putamen on each
section, and the spatial average fluorescence intensity within the
ROI was calculated using ImageJ (National Institutes of Health;
Bethesda, MD). The diameter of the ROI was selected to be the
same as the FUS transducer lateral focal region dimension
(1.2 mm). The reported fluorescence intensity for each side of the
brain was the sum of the calculated fluorescence intensities within
the ROI of all nine sections.
Statistical analysis
An unpaired two-tailed Student’s t-test using GraphPad Prism
(Version 5.01, La Jolla, CA, USA) was used to compare between
groups. A P value of 0.05 was considered to represent a significant
difference in all the analyses. All data were expressed as mean 6
standard deviation.
Results
IN delivery to the brain
Figures 2A and 2B present representative fluorescence images
of horizontal sections of the whole brain from the control group
(group 1) and IN sham group (group 2). As shown in Fig. 2B, IN
administration of the dextran without FUS resulted in an elevation
of dextran concentration in the whole brain. A statistically
significant increase in the fluorescence intensity was found in the
IN sham group when compared with the control group (Fig. 2C),
suggesting that the IN route enables direct access of drugs to the
brain. Within each group, no difference was found between left
and right caudate putamen regions, as expected. However, the
delivered dextran did not accumulate in any particular brain
region and the concentration achievable in different regions of the
brain varied, which confirmed the non-targeted nature of IN
administration.
FUS-enhanced IN delivery
Figures 3A and 3B show that FUS exposure in the presence of
microbubbles significantly enhanced IN delivery at the targeted
left caudate putamen (Fig. 3A) when compared with the contra-
lateral right side with IN administration only (Fig. 3B). Quanti-
fication of the fluorescence intensities of mouse brains in the FUS+
IN group found an 8-fold increase in the fluorescence intensity
compared with the contralateral control side with IN only
(Fig. 3E).
When IV injection was used for dextran delivery instead of IN,
localized dextran accumulation was observed at the targeted
caudate putamen. Figures 3C and 3D display representative
fluorescence images from the FUS+IV treated (left) caudate
putamen and contralateral non-treated (right) side with IV dextran
injection only. The two mouse brains shown in Figs. 3A, B and
3C, D had fluorescence intensities of similar magnitude (27.2 and
19.4, respectively). When comparing across the entire FUS+IN
and FUS+IV groups, the administration route did not appear to
affect the delivery efficiency in the targeted caudate putamen as no
significant difference in dextran accumulation was detected
between FUS+IN and FUS+IV groups (P= 0.48; Fig. 3E). In
addition, a significant increase in fluorescence intensity was found
in the IN only group (Fig. 3B) compared with IV only group
(Fig. 3D) (P= 0.005; Fig. 3E), further confirming that IN admin-
istration alone allows the dextran to gain direct access to the brain.
It should be noted that although the fluorescence intensities of
FUS+IN and FUS+IV groups were at a similar level, distinct
dextran distribution characteristics were observed, as representa-
tively shown in Figs. 3A and 3C. Images shown in Fig. 3A–D were
acquired at higher magnification than those presented in Fig. 2 to
highlight the features of dextran distribution. A single sonication
following IV dextran injection resulted in a more homogeneous
dextran distribution within the FUS targeted region (Fig. 3C),
while a less homogeneous dextran distribution with high intensity
regions was observed in the FUS+IN group (Fig. 3A). Heteroge-
neous dextran distribution was also observed on the contralateral
control side with IN administration only as shown in Fig. 3B as
well as Fig. 2B. In addition, it was clearly observed in Fig. 3B that
the vascular network was highlighted by the dextran, confirming
that IN administered compounds can be transported within the
perivascular spaces of cerebral blood vessels [7].
Preliminary safety assessment of FUS sonication was performed
by histological analysis. Minor microhemorrhages were observed
in both FUS+IN and FUS+IV groups. Figures 4C and 4D depict
cases with the most severe damage from the FUS+IN and FUS+IV
groups, respectively. Small clusters of erythrocyte extravasation
were observed in both cases. Figure 5 shows the microbubble
activities detected in these two groups, as quantified by stable and
inertial cavitation doses. No significant difference in stable or
inertial cavitation dose was found between the FUS+IN and FUS+
IV groups.
Discussion
Our findings validated the hypothesis that FUS can enhance the
delivery of IN-administered drugs at a targeted brain location. It is
the first time that this novel combination of these two different
platform techniques is proposed. Numerous studies have demon-
strated that the IN route can provide a non-invasive approach for
brain drug delivery, but none of them have shown that an
enhanced delivery at a targeted location was possible. The FUS+
IN technique offers a potentially useful drug delivery platform for
treating CNS diseases.
Focused Ultrasound-Enhanced Intranasal Drug Delivery
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By combining FUS with IN drug delivery, we achieved a
significant increase in drug accumulation in the targeted brain site,
thus improving the bioavailability and biodistribution of the IN
administered drug. We confirmed that IN-administered dextran
could be delivered to the brain, bypassing the BBB, but it had low
delivery efficiency and was non-targeted (Fig. 2). IN administra-
tion in combination with FUS achieved an 8-fold increase in drug
delivery efficiency within the targeted region compared with IN
administration only (Fig. 3E). In the past, the IN route could only
be used for particularly potent substances because of limited
absorption across the nasal epithelium [6]. FUS+IN may expand
its application to a much broader range of drugs. Moreover,
although IN administrated drugs are distributed to the whole
brain, by decreasing the IN administration dose, FUS+IN has the
potential to achieve therapeutic drug level only within the targeted
site while keeping non-targeted sites at sub-therapeutic level.
Therefore, the FUS technique would potentially overcome the
major disadvantages of IN brain drug delivery: (1) overcome the
restriction that the IN route can only be used for particularly
potent substances and (2) achieve targeted brain drug delivery.
FUS+IN can be applied in the future for the delivery of drugs that
have been previously shelved from IN administration due to their
Figure 2. Fluorescently-labeled dextrans delivered to the whole brain through IN administration. (A) and (B) show the representative
fluorescence images of horizontal sections of the whole brain from the control group (no FUS and no dextran administration) and the IN sham group
(IN administration without FUS), respectively. The caudate putamen regions are highlighted by dash lines. (C) Quantitative analysis of the
fluorescence intensities within the left and right caudate putamen regions for these two groups. IN administration resulted in a significant increase in
the fluorescent intensity compared with the control. Scale bar represents 1 mm.
doi:10.1371/journal.pone.0108880.g002
Figure 3. Focused ultrasound enhanced targeted delivery of the dextran administered through IN or IV route. (A) and (B) show
fluorescence images of part of the left and right caudate putamen in one horizontal section from one mouse in the IN treatment group. (C) and (D)
show part of the left and right caudate putamen in one horizontal section from one mouse in the IV treatment group. FUS was targeted at the left
caudate putamen. The caudate putamen region in each image was highlighted by the dash line. The box insert in (B) is a blow up of the square area
in (B), which shows that the vascular network was highlighted by the dextran, confirming that IN administered compounds can be transported within
the perivascular spaces of cerebral blood vessels. (E) Quantitative fluorescence intensity analysis within the left and right caudate putamen regions
for these two groups. FUS significantly enhanced IN delivery efficiency. No difference was found between FUS+IN and FUS+IV. Scale bar represents
1 mm.
doi:10.1371/journal.pone.0108880.g003
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Figure 4. Whole brain histological examinations by hematoxylin and eosin (H&E) staining. Microscopic examination of (A, C) left
(sonicated) and (B, D) the corresponding right (nonsonicated) caudate putamen in H&E stained horizontal sections. (A) and (B) were from the same
section of a mouse brain with the most severe damage in the FUS+IN group. (C) and (D) were from the same section of a mouse brain with the most
severe damage in the FUS+IV group. Minor microhemorrhages, as pointed out by arrows, were observed on the FUS targeted left caudate putamen
in (A) and (C). No tissue damage was observed on the contralateral right caudate putamen without FUS sonication in (B) and (D).
doi:10.1371/journal.pone.0108880.g004
Figure 5. Quantification of microbubble cavitation activities in FUS+IN and FUS+IV groups. (A) Stable cavitation doses. (B) Inertial
cavitation doses. No difference was found in both stable cavitation behavior and inertial cavitation behavior between these two groups.
doi:10.1371/journal.pone.0108880.g005
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poor pharmacokinetics. New CNS therapeutic strategies could
emerge based on the FUS+IN technique.
Our findings should not be interpreted as if to establish that the
IN administration when combined with FUS is superior for
targeted brain drug delivery than FUS+IV. On the contrary,
FUS+IV is better at targeted delivery than FUS+IN. IN
administration is associated with drug delivery to the whole brain,
whereas the dextran injected through IV can only be delivered at
the FUS targeted region where the BBB was opened. Therefore,
for drugs exhibiting high stability in circulation and low systemic
side-effects, such as dextrans (the half-life of the 40 kDa dextran in
blood is about 7.5 hours [35]) used in this study, FUS+IV remains
an effective technique since it provides drug access only to the
targeted location without affecting other CNS sites. However, IN
administration offers a non-invasive alternative over the more
conventional IV injection for brain drug delivery. It allows direct
access to the CNS and has low systemic bioavailability [22].
Therefore, FUS+IN may become a viable alternative for FUS+IV
in the delivery of therapeutics that have beneficial effects within
the CNS, but short half-lives in the blood and/or high systemic
side effects. IN delivery of such therapeutics, such as neurotrophic
factors, neuropeptides, and hormones, have been shown promise
in the treatment of CNS diseases and injuries, including
Alzheimer’s disease, stroke, Parkinson’s disease, motor neuron
diseases, demyelinating diseases and traumatic brain injury
[6,8,22]. The combination of IN administration and FUS has
great potential to improve treatment outcomes of these diseases
compared with IN administration alone.
We clearly showed brain uptake of the IN administrated
dextran in both the IN only group and FUS+IN group (Figs. 2B,
3A, and 3B). In addition, we found the FUS+IN group showed less
homogeneous dextran distribution (Fig. 3A) than the FUS+IV
group (Fig. 3C). Similar heterogeneous dextran distribution was
also observed in the IN only group (Figs. 2B and 3B). For drug
delivery by FUS+IV, the drug circulated throughout the body and
significant CNS delivery can only be achieved in brain locations
where BBB opening is induced by FUS with microbubbles through
cellular mechanisms, including opening a part of the tight
junctions, formation of channel and fenestration in endothelial
cell cytoplasm, and enhancing transcytosis [36]. On the other
hand, IN administered drugs are most likely transported along the
olfactory and trigeminal nerves to the brain entry sites and then
distribute to other distant CNS sites via convective and diffusive
transport from the cerebral perivascular spaces into the paren-
chyma [4,6]. Figure 3B confirmed that IN-administered drugs can
be transported within the perivascular spaces of cerebral blood
vessels. The distribution of IN-administered drugs in the brain will
be affected by the structural characteristics of the different brain
compartments and the functional barriers between them [22],
which may contribute to the observed heterogeneous dextran
distribution. Future investigation is needed to better understand
the pharmacokinetics of drug delivery by FUS+IN.
Further investigation is warranted on the mechanisms for FUS-
enhanced IN drug delivery. It has been demonstrated that FUS
and microbubbles can generate shear stress on the tissue and
increase hydraulic conductivity of the interstitial space, leading to
increased drug diffusion [26]. Thus, the diffusion of drugs in the
perineural and perivascular spaces may be enhanced by the FUS
technique. Meanwhile, it has been proposed that the most likely
convective mechanism for the widespread distribution of IN
administered drugs is the convective flow induced by the
expansion and contraction of the perivascular spaces with the
cardiac cycle, named ‘‘perivascular pump’’ [4,37]. Microbubble
cavitation can cause expansion and contraction of the perivascular
spaces, similar to the expansion and contraction induced by the
cardiac cycle but at a much higher frequency [27]. The
displacements of the perivascular spaces may induce bulk flow,
leading to enhanced convective transport within cerebral perivas-
cular spaces at the FUS targeted region. Furthermore, drugs that
enter the systemic circulation through the IN route can cross the
BBB at the FUS targeted regions. Therefore, the combination
effects of FUS-enhanced local drug diffusion, convective transport,
and BBB permeability may contribute to FUS-enhanced IN drug
delivery. Ongoing efforts include unveiling the mechanisms by
which FUS technique enhances the drug delivery after IN
administration.
Whole brain histological examination showed minor micro-
hemorrhages within the FUS targeted region. The damage
induced by the FUS technique for FUS+IN and FUS+IV groups
were similar (Fig. 4). Figure 5 confirmed that no difference was
found in microbubble activities between these two groups. We
note that the standard deviations of stable and inertial cavitation
doses for FUS+IN group were higher than those for the FUS+IV
group. The mice in the FUS+IV group were treated within one
day using the same batch of microbubbles; while the mice in the
FUS+IN group were treated on separate days using different
batches of microbubbles, which could explain the higher standard
deviations in microbubble activities observed in the FUS+IN
group compared with the FUS+IV group. Nevertheless, these
findings suggest that the likelihood of tissue damage by FUS was
only correlated with the applied acoustic exposure, not the dextran
administration route. The minor damaging effect is consistent with
that observed in previous studies [20,21]. Previous short-term (up
to 5-hr survival) and long-term (up to 4-wk survival) safety
assessment of the FUS technique demonstrated that the damaging
effect, characterized by the presence of a small number of
extravasated blood cells within the sonicated region, were found to
be transient as no evidence for continuous damage was seen
[20,21]. Behavioral tests performed in non-human primates after
repeated FUS sonication in combination with microbubbles
showed that FUS did not cause any functional damage even in
the presence of tiny clusters of extravasated blood cells [38].
Furthermore, the minimal microhemorrhage could be eliminated
by decreasing the FUS exposure [39]. Future studies will optimize
the FUS+IN treatment parameters for efficient drug delivery
without any tissue damage and explore its potential as a new drug
delivery platform in treating CNS diseases.
Conclusions
IN administration is a promising approach for brain drug
delivery. The present study demonstrated for the first time that
FUS can enhance IN drug delivery efficiency at the targeted brain
location. Despite the fact that the IN route has limited drug
absorption across the nasal mucosa, the FUS+IN technique
achieved similar drug delivery efficiency within the targeted region
compared with the conventional FUS+IV approach. Future
studies will explore its potential as a drug delivery platform in
treating CNS diseases.
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